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[57] ABSTRACT 
The presently-disclosed IPC synthase-inhibitor assays com 
prise the steps of: (1) expression of the IPC1 gene in a cell; 
(2) introducing labeled starting substrates for ceramide 
conversion as Well as potential inhibitor(s) of such conver 
sion to the expressed gene product in an environment Which 
alloWs time and conditions for conversion, and (3) identi 
fying those potential inhibitors Which actually inhibit con 
version. The present invention also provides methods to 
determine the ability of a test compound to inhibit fungal 
groWth, comprising the steps of (1) presenting active inosi 
tolphosophotidylceramide synthase in a manner such that 
synthesis of inositolphosphotidylceramide can occur; (2) 
introducing ceramide and phosphotylinositol, said ceramide 
or phosphatidylinositol carrying label for identi?cation; (3) 
subjecting said active inositolphosophotidylceramide 
synthase, ceramide and phosphotylinositol to ordinary con 
ditions necessary for ceramide conversion to phosphoinosi 
tol ceramide; and (4) identifying those test compounds 
Which inhibit ceramide conversion to phosphoinositol cera 
mide. 
17 Claims, 3 Drawing Sheets 
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FUNGAL IPC SYNTHASE ASSAY 
This application claims bene?t of US. Provisional 
Application No. 60/028,079, ?led on Oct. 7, 1996. 
BACKGROUND OF THE INVENTION 
In sphingolipid biosynthesis of fungi, 
inositolphosphorylceramide(IPC) synthase is responsible 
for transferring inositol phosphate from phosphatidylinositol 
to the fungal ceramide to form inositolphosphorylceramide. 
The presence of inositolphosphorylceramides have been 
demonstrated in yeast (S. cerevisiae) and in pathogenic fungi 
(C. albicans, Aspergillus fumigatus, H. capsulatum). Lester 
& Dickson, 26 Adv. Adv. Lipid Res. 253 (1993). It is also 
knoWn that in the model yeast, S. cerevisiae, inositolphos 
phosphingolipids are essential for viability. Wells et al., 178 
J. Bacteriol. 6223 (1996). 
Moreover, although elements of the synthetic pathWay for 
sphingolipids in fungi are shared by mammalian sphin 
golipid synthesis, the pathWay is divergent at the step after 
formation of ceramide. Martin & Pagano, 159 Anal. Bio 
chem. 101 (1986). Thus, inhibitors of IPC synthase are likely 
candidates for antifungal chemotherapy. 
In a copending application, Ser. No. 08/882,767, Dickson, 
Lester and Nagiec characteriZed the IPC synthase gene 
(IPC1). In that application, the DNA sequence of IPC1 is 
disclosed, as is the corresponding amino acid sequence of 
the enZyme. 
SUMMARY OF THE INVENTION 
The present invention relates generally to an assay for 
inhibitors of IPC synthase. Because this invention makes 
high-throughput screening of potential inhibitors possible, 
the identi?cation of lifesaving treatments using the assays 
disclosed herein is more likely. 
In one embodiment of the present invention, the assays 
comprise expression of the IPC1 gene in a cell, introduction 
of labeled starting substrates for ceramide conversion as 
Well as potential inhibitor(s) of such conversion to the 
expressed gene product in an environment Which alloWs 
time and conditions for conversion, and identifying those 
potential inhibitors Which actually inhibit conversion. 
Preferably, the labeled starting substrates are radiolabeled, 
?uorescent or biotinylated derivatives of the fungal ceram 
ide. Moreover, a method for identifying compounds Which 
inhibit IPC synthase by using derivatiZed analogs of the 
fungal ceramide as a potential acceptor for the inositol 
phosphate moiety by fungal IPC synthase is also disclosed. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 Synthesis of biotinylated fungal ceramide deriva 
tive. 
FIG. 2 Schematic SPA assay for IPC synthase using 
biotinylated fungal ceramide. 
FIG. 3 DerivatiZed Ceramide Analogues Useful for IPC 
Synthase Assays 
DETAILED DESCRIPTION OF THE 
INVENTION 
The presently-disclosed IPC synthase-inhibitor assays 
comprise the steps of (1) expression of the IPC1 gene in a 
cell; (2) introducing labeled starting substrates for ceramide 
conversion as Well as potential inhibitor(s) of such conver 
sion to the expressed gene product in an environment Which 
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alloWs time and conditions for conversion; and (3) identi 
fying those potential inhibitors Which actually inhibit con 
version. In one embodiment, the IPC1 gene is overexpressed 
so as to provide excess available IPC synthase. In order to 
transfect and/or overexpress the IPC1 gene, one in the art 
can use conventional methods (ie. J. Sambrook et al., 
Chapter 16, Molecular Cloning: A Laboratory Manual, 2d 
ed., Cold Spring Harbor Press (1989)) and the materials 
disclosed in Example 2. 
Expression of the IPC1 gene can take place in any knoWn 
cell line Which is capable of expression of genes. Preferred 
cell types include E. coli, S. cerevisiae and S. pombe. 
HoWever, human pathogenic fungal cells may also be used, 
including, for example, C. albicans, C. parapsilosis, C. 
glabrata, C. tropicalis, C. krusei,A. fumigatus,A. ?avus and 
C. neoformans. Moreover, any expression vectors are useful 
in the present invention, but vectors useful to overexpress 
the gene are preferred. For example, the baculovirus expres 
sion system is useful in the present invention. Summers & 
Smith, TexasAgric. Exp. Stn. Bull. 1555 (1987). In addition, 
preferred vectors include: pYX212; pYX213; pYX012; 
pYX013; YEp 24 and Yrp7. These vectors can be commer 
cially obtained. The ?rst four in the list can be obtained from 
Novagen. YEp 24 is available from American Tissue Type 
Culture Collection (ATCC) under Accession Number 37051. 
Yrp7 Was disclosed in Struhi et al., 76 Proc. Nat. Acad. Sci. 
1035 (USA. 1979). Regulatory or cis-regulatory sequences 
of the expression vector are preferably those useful for 
overexpression as Well. For instance, those that have 
galactose-inducible promoters are most preferred. 
The starting substrates useful for the present invention can 
be any ceramides Which are capable of being converted from 
the ceramide to the inositolphophorylceramide and are 
capable of being labeled. In particular, C2—C12 ceramides are 
preferred for use in this assay. In particular, NBD-C6 
ceramide and BODIPY-CS-ceramide are useful in this inven 
tion. The label can be on either the PI or the ceramide 
substrate. Moreover, N-hexanoyl-sphingosine appears to be 
an effective substrate for IPC synthase. R groups on 
N-hexanoyl-sphingosine can be biotin, 4-nitrobenZo-2-oxa 
1,3 diaZole (NBD), 8-methyl-4,4-di?uoro-1,3,5,7 
tetramethyl4-bora-3a,4a-diaZa-3-indacene (BODIPY), or 
any other small molecule hapten Which an antibody can 
recogniZe. Any other ?uorescent moiety can also substitute 
for NBD or BODIPY. 
Radioactive materials, in particular tritium or radioactive 
phosphorous, such as 32P or 33P, or carbon, such as 14C, or 
?uorescent materials are useful in the present invention. 
Radiolabeled and chromogenic substrates are commercially 
available from Amersham (2636 South Clearbrook Drive, 
Arlington Heights, 111., 60005 (800-341-7543)) or Dupont 
NeW England Nuclear (1007 Market Street, Wilmington, 
Del. (800-441-7515)) and Molecular Probes, Inc. (PO. Box 
22010, Eugene, Oreg. 97402-0469 (800-438-2209)), respec 
tively. Substrates can be labeled by any useful means. Those 
in the art recogniZe that many ?uorescent markers and 
probes can be used, and are aWare of the methods to make 
such markers and probes. Typical materials and means for 
labelling are described in Martin and Pagano, 159 Anal. 
Biochem. 101 (1986). 
In another embodiment of the invention, phytosphin 
gosine (available from Sigma) can be derivatiZed With biotin 
by acylation of the free amine With a biotinylated spacer 
arm. This procedure provides an analog of the fungal 
ceramide With a molecular handle (FIG. 1). The analog can 
then be used as an acceptor molecule and conjugated (pre 
reaction or post reaction) to streptavidin derivatiZed solid 
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substrate such as SPA beads or derivatiZed af?nity chroma 
tography materials for separation of radio-labeled ceram 
ides. Reaction With tritiated phosphatidylinositol as the 
donor Would result in scintillation of the SPA by proximity 
of the neWly derivatiZed ceramide (FIG. 2). Alternatively, 
labeled streptavidin bound to biotinylated conversion prod 
uct can be ?lter-separated. Also, antibodies can be used to 
identify hapten-labeled conversion products. 
Conditions for conversion can be any of those knoWn in 
the art, and can be in vivo or in vitro. One preferred 
condition is the use of crude or puri?ed membrane 
preparations, incubated according to Becker and Lester, 142 
J. Bacterial. 747 (1980) and Ko et al., 176 J. Bacterial. 5181 
(1994). 
Prior to the present invention, it Was not knoWn that 
inositolphosphotidyl synthase Was an essential enZyme for 
fungal groWth. That is, although the activity of IPC synthase 
Was knoWn, it Was not knoWn that a cell lacking in IPC 
synthase activity Would not groW. Therefore, the present 
invention provides methods for determining a compound’s 
ability to inhibit fungal groWth. In particular, the present 
invention provides a method to determine the ability of a test 
compound to inhibit fungal groWth, comprising the steps of 
(1) presenting active inositolphosophotidylceramide syn 
thase in a manner such that synthesis of inositolphosphoti 
dylceramide can occur, (2) introducing ceramide and 
phospsphotylinositol, said ceramide or phosphatidylinositol 
carrying label for identi?cation; (3) subjecting said active 
inositolphosophotidylceramide synthase, ceramide and 
phosphotylinositol to ordinary conditions necessary for 
ceramide conversion to phosphoinositol ceramide; and (4) 
identifying those test compounds Which inhibit ceramide 
conversion to phosphoinositol ceramide. 
Preferred methods to determine a compound’s ability to 
inhibit fungal groWth are those Wherein the active inositol 
phosophotidylceramide synthase is presented either as a 
Whole cell culture or a membrane preparation from a human 
pathogenic fungal cell culture. HoWever, any fungal cells are 
useful in the present invention. The strains that are particu 
larly easy to groW and maintain in a laboratory setting are 
preferred for these methods. Certain human fungal cells are 
listed here to exemplify the human fungal strains Which may 
be used in the present inventive method: C. albicans, C. 
parapsilasis, C. glabrata, C. trapicalis, C. krusei, A. 
fumigatus, A. ?avus and C. neafarmans. 
EXAMPLES 
Example 1 
IPC1 Complementation of IPC Synthase Defect by 
IPC1 
A. Identi?cation of IPC1 defective cell. 
Strains, plasmids, and culture conditions: S. cerevisiae 
strains are: 7R6 (MATa ura3-52 leu2-3,112 lcb1::URA3 
SLC1-1 ade1) (Dickson et al., 10 Mal. Cell. Bia. 2176 
(1990)) Which Was derived from Wild type strain SJ21R 
(MATa ura3-52 leu2-3,112 ade1); YPH250 (MATa ura3-52 
lys2-801mb” ade2-1010Chre trp-A1 his3-A200 leu2-A1) 
(available from the ATCC, and useful to make the other 
strains, by common means); AG27-61 (MATa ura3-52 leu2 
3,112 lcb1::URA3 SLC1-1 ade1 lys2-801amber ipc1-1) Was 
derived from 7R6 by the procedure described beloW. 
pRS315 is a standard yeast vector and described in Sikorski 
et al., 122 Genetics 19 (1989). 
Yeast Were groWn on modi?ed PYED (bufferred to pH 
5.0, PYED-5.0) Which contained 1% yeast extract (Difco), 
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2% Bacto Peptone (Difco), 2% or 4% glucose, 50 mM 
sodium succinate (pH 5.0), inositol (50 mg/liter), and potas 
sium phosphate monobasic (50 mg/ml (Buede et al., 173 J. 
Bacterial. 7180 (1991)), or on de?ned medium supple 
mented as described (Buede, ibid) and containing, When 
necessary, 25 pM (or other indicated concentration of) 
phytosphingosine (PHS). PYED buffered to pH 4.1 (PYED 
4.1) Was made by mixing 290 ml of autoclaved agar (2% for 
plates only), 300 ml of autoclaved yeast extract (1%) plus 
peptone (2%), 100 ml of ?lter steriliZed glycine (0.5 M, pH 
3.1), 200 ml of glucose (20%), 10 ml of inositol (0.5%), and 
100 ml of potassium phosphate monobasic (0.5%). The pH 
Was 4.1. 
A diploid version of strain AG27-61 (termed AGD27-61) 
Was made by transforming haploid cells With a plasmid 
(pHO-12 (Russell et al., 6 Mal. Cel. Bia. 4281 (1986)) 
carrying the HO endonuclease gene, responsible for sWitch 
ing of the mating type. Leu+ transformants Were streaked 
onto PYED plates and colonies containing MAT a/MATalpha 
diploid cells Were identi?ed by their large, ellipsoidal mor 
phology. Diploids Were screened on de?ned medium lacking 
leucine for Leu- cells, indicating loss of the plasmid carrying 
the HO gene, and tested for transformation ef?ciency using 
pRS315 (LEU2 CEN4). 
Genomic DNA library 
A recombinant DNA library containing about 160,000 
plasmids, 95% of Which carried an insert, Was constructed. 
Genomic DNA from derivatives of strain 4R3 resistant to pH 
4.1 Was isolated, pooled, and 10 pig Was partially digested 
With Sau3AI. DNA fragments of 5 to 10 kb Were isolated 
from an agarose gel and ligated With 1 pig of BamHI 
digested, alkaline phosphatase-treated pRS315. Ligated 
DNA Was puri?ed using GeneClean (Bio101, LaJolla, 
Calif.), electroporated into E. cali XL1-Blue cells 
(Stratagene, LaJolla, Calif.), and plasmid DNA Was prepared 
from ampicillian-resistant colonies selected on petri plates. 
Miscellaneous reagents 
For some experiments, the agar in petri plates Was 
replaced With agarose (Fisher, BP160-500). pIPC1 is a 
plasmid isolated from the recombinant DNA library 
described above in Which the 4307 base pair insert corre 
sponds to S. cerevisiae Chromosome XI betWeen coordi 
nates 432,813 and 437,119 as described in the Saccharamy 
ces cerevisiae genome database at Stanford University 
(http://genome.WWW.stanford.edu). 
Isolation of strain AG27-61 
Strain 7R6 Was groWn overnight in PYED plus 25 pM 
PHS (referred to here as the medium) and then mutageniZed 
With ethylmethanesulfonate to give 20% killing as described 
in Pinto et al., 174 J. Bacterial. 2565 (1992). MutageniZed 
cells Were diluted to an absorbance at 600 nm (A600) of 0.4 
With medium, incubated With shaking at 30° C. for 7 h, 
during Which time the A600 increased to 2.5, centrifuged, 
resuspended in 2 ml of medium and sonicated using a 
microtip (Heat Systems-Ultrasonic) for 2 min to disrupt 
clumped cells. One ml of cells Was layered on 4 ml of 30% 
sodium diatriaZoate (see Pinto et al., 174 J. Bacterial. 2565 
(1992)) and centrifuged at 10° C. in a Sorvall RT6000B 
centrifuge for 4 min at 2000 rpm. Most cells Were at the 
interface but a faint pellet of dense cells Was present at the 
bottom of the tube. The liquid Was aspirated and the cell 
pellet Was carefully resuspended in 0.5 ml of medium to 
avoid mixing With cells stuck to the side of the tube. 
Resuspended pellets from tWo tubes Were mixed and 
re-centrifuged on 30% sodium diatriaZoate. The cell pellet 
Was resuspended in medium and about 500 cells Were spread 
on PYED plates containing 25 pM PHS. TWo days later only 
6,022,684 
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about 15 colonies per plate Were visible, suggesting only 3% 
of the dense cells Were viable. 
Putative mutants Were screened to differentiate those 
speci?cally defective in sphingolipid synthesis from those 
defective in other lipid biosynthetic pathWays Which might 
also affect cell density. The screen Was based upon the 
observation that strain 7R6 cannot groW at loW pH When it 
lacks sphingolipids (no PHS present in the medium) but can 
groW When alloWed to make sphingolipids (PHS present in 
the medium, Patton et al., 1992, J. Bacteriol. 
174:7180—7184). Thus, about one hundred mutants unable 
to groW on PYED plates at pH 4.1 either in the presence of 
25 mM PHS Were identi?ed. 
Mutant strains Were examined further for a defect speci?c 
to sphingolipid synthesis relative to glycerophospholipid 
synthesis by looking for decreased incorporation of [3H] 
inositol-containing sphingolipids relative to phosphatidyli 
nositol (ZWeerink et al. 1992 J. Biol. Chem. 
267:25032—25038). By this assay, strain AG27-61 appeared 
to be speci?cally defective in sphingolipid synthesis. 
[3H]N-acetylsphinganine labeling of sphingolipids in 
v1vo 
Cellular conversion of [3H]N-acetylsphinganine to IPC 
Was measured as folloWs. PYED medium Was added to tubes 
containing solid [3H]N-acetylsphinganine (860 cpm/pmole) 
and the mixture Was dissolved by treatment for ?ve minutes 
in an ultrasonic Water bath. Log phase cells, groWn in PYED 
medium, Were centrifuged, suspended in fresh medium and 
added to the radiolabeled medium to give a ?nal cell density 
of 1.5 A600 units/ml. The ?nal concentration of 
N-acetylsphinganine Was 5.0 pM. At the indicated times, 1 
ml samples Were removed, quenched With trichloroacetic 
acid, and processed as in the inositol-labeling procedure. 
Qualitative analysis of 25 pl samples Was carried out on 
20 cm Whatman HP-K plates developed With 
chloroform:methanol:4.2N NH4OH (9:7:2). Each lane con 
tained 2 nmoles of IPC-3 (IPC With a monohydroxylated 
fatty acid, 2) internal standard. Radioactivity Was measured 
by using a BioScan apparatus and the plates Were sprayed 
With a 10% solution of CuSO4.5H2O in 8% H3PO4 and 
charred at 160° C. to locate the IPC-3 standard. 
Quanti?cation of radioactive products Was achieved by 
ascending chromatography of 5 pl samples on Whatman 
SG-81 paper Washed With ethylenediamine tetraacetate (see 
Steiner and Lester, 260 BBA 222 (1972)) and developed With 
chloroform methanol:4.2N NH4OH (9:7:2). The lanes Were 
cut into one cm Zones and counted in a liquid scintillation 
spectrometer. 
In vitro assay of IPC synthase 
The inventors elected to develop a less time consuming 
assay for measuring IPC synthase activity than the published 
assay Which uses chromatography to separate radiolabeled 
substrate from product, IPC (Becker and Lester, 142 J. 
Bacteriol. 474 (1980), K0 et. al., 176 J. Bacteriol. 5181 
(1994)). The improved procedure separates the substrate and 
product by differential solvent extraction. A substrate mix 
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phosphatidylinositol, membranes, and Water to 200 pl total 
volume. Typically 75—300 pg of membrane protein Were 
added per reaction. The membrane proteins Were prepared 
according to Pinto et al., 174 J. Bacteriol. 2575 (1992), 
except that the buffer contained 1 pig/ml of leupeptin, 
pepstatin and aprotinin and, in addition, the cells Were 
shaken With glass beads for 6 thirty second intervals With a 
2 minute period for cooling on ice betWeen the intervals. The 
reaction mixture Was sonicated for 1 min in an ultrasonic 
Water bath before addition of membranes and then incubated 
for 15 or 30 min at 30° C. With gentle shaking. The reaction 
Was stopped by addition of 2.8 ml of 96.43% methanol (?nal 
methanol concentration of 90%). After standing for 10 min 
the mixture Was centrifuged at room temperature. TWo ml of 
the supernatant ?uid Were mixed With 4 ml of tert-butyl 
methyl ether (Sigma-Aldrich, HPLC grade), then With 2 ml 
of Water, folloWed by vortexing, and centrifugation. The 
loWer phase containing the product of the reaction Was 
extracted tWice more With 4 ml portions of mock upper 
phase, prepared by mixing 2 parts of reaction mixture 
(lacking N-acetylsphinganine, phosphatidylinositol, and 
membranes) With 4 parts of tert- butyl methyl ether plus 2 
parts of Water. The volume of the loWer phase Was measured, 
and 1 ml Was added to 4 ml of scintillation cocktail and 
counted in a liquid scintillation spectrometer. The cocktail 
contained 4 gm/l of 2-(4‘-t-butylphenyl)-5-(4‘-biphenylyl) 
1,3,4-oxadiaZole, 3 gm/l of 2-(4‘-biphenylyl)-6 
phenylbenZoxaZole, 33.3% Triton X-100, and 66.7% tolu 
ene. IPC synthase activity Was expressed as pmoles of IPC 
made/min/mg protein. 
Alternative in vitro assay for IPC Synthase—the ?lter 
binding assay 
This assay is based on the difference in charge betWeen 
the substrate for IPC synthase, N-acetylsphinganine 
(uncharged) and the product, IPC (negatively charged). Test 
reactions Were performed to determine if the charge differ 
ence betWeen substrate and product could be the basis for an 
assay procedure. The test reactions shoWed that N-acetyl 
[3H]sphinganine-P-Inositol (IPC) binds tightly to the fol 
loWing anion-exchange ?lter papers (all made by Whatman): 
AE30, aminoethylcellulose; AE81, aminoethylcellulose; 
and DE20, diethylaminoethylcellulose. An enZyme reaction 
mixture Was prepared in a volume of 100 pl to give these 
?nal concentrations: 100 mM TRICINE (pH 8.1), 0.02% 
Tergitol, 1 mM phosphatidylinositol, 100 pg of membrane 
protein, prepared as for the in vitro assay of IPC synthase 
described above. The reaction also contained either N-acetyl 
[3H]sphinganine (152550 cpm, 67 pmoles) or N-acetyl-[3H] 
sphinganine-P-Inositol (251700 cpm, 110 pmoles). The 
reaction Was immediately quenched by adding 9 volumes of 
95% ethanol. Samples (20 pl) Were applied to 2.3 cm 
diameter DE20 and DE81 ?lters and air dried. The ?lters 
Were Washed With 95% ethanol and radioactivity Was mea 
sured by counting in a liquid scintillation spectrometer. The 
results are shoWn beloW: 
N-acetyl-[3H]sphinganine-P-Inositol 
N—acetyl[3H]sphinganine 
DE20 DE81 
(% Original Radioactivity on Discs) (% Original Radioactivity on Discs) 
109 90.4 
2.6 1.4 
ture containing 50,000 cpm of [3H]N-acetylsphinganine and 
20 nmoles of N-acetylsphinganine, Was added to a plastic 
tube, and dried using a stream of N2. The dry mix Was 
suspended in 50 pl of 0.2 M potassium phosphate, pH 7.0, 
20 pl of 20 mM CHAPS (Sigma), 40 pl of 5 mM aqueous 
65 These data demonstrate that the substrate N-acetyl[3H] 
sphinganine barely binds to the ?lter paper under the solvent 
conditions used, While the charged product N-acetyl-[3H] 
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sphinganine-P-Inositol binds very Well. These results pro 
vide a simple and fast assay for IPC synthase enzyme 
activity. 
Preparation of [4,5-3H]N-Acetylsphinganine 
N-acetylsphingosine Matreya, Inc.) Was reduced in etha 
nol With Tritium gas (American Radiochemicals, Inc.) in the 
presence of Adams catalyst. The sample Was dried, dis 
solved in 0.2 ml chloroform, and applied to a 05x50 cm 
column of Adsorbosil (100/200 mesh) preWashed With chlo 
roformzmethanol (1:1) and equilibrated With chloroform. 
The elution schedule Was: 14 ml of chloroform folloWed by 
chloroform-methanol (97:3), collecting 7 ml fractions. Frac 
tions 11—16 Were pooled, dried, dissolved in methanol, 
applied to silica gel thin layer plates (Whatman LK5) and 
developed With chloroformzmethanol (95:5). The appropri 
ate Zone, located by autoradiography, Was scraped and 
transferred to a syringe ?tted With a Te?on ?lter (Acro 
LC3S, 0.45”, Gelman Sciences, Inc,). The [3H]N 
acetylsphinganine Was eluted With 8 ml of methanol. The 
thin layer chromatography step Was repeated. The ?nal 
product, With the same mobility as authentic 
N-acetylsphinganine prepared according to a published pro 
cedure (Gaver and SWeeley, 88 J. Am. Chem. Soc. 3643 
(1966)), had a speci?c activity of 1.5><107 dpm/nmole. 
Miscellaneous procedures 
Yeast Were transformed using LiOAc-treated cells (GietZ 
et. al., 8 Nucleic. Acids. Res. 1425 (1992)). Protein concen 
tration Was determined With the Bradford reagent using 
bovine serum albumin as standard (BioRad Inc.). 
B. Isolation of the IPC1 gene. 
A gene that complemented the defect in AG27-61 could 
not be isolated directly from the haploid because the strain 
transformed at too loW a frequency, about one transformant 
per microgram of plasmid DNA. Since diploid yeast strains 
are generally more vigorous, a diploid version of AG27-61 
Was examined and found to be transformed at a high enough 
frequency to alloW screening of a recombinant DNA library. 
One diploid strain, designated AGD27-61, Was transformed 
With a recombinant DNA library carried in pRS315. Apool 
of about 3000 Leu+ transformants Was treated With 10 pM 
phytosphingosine (PHS) to enrich for the desired transfor 
mant. The rationale for this treatment Was based upon the 
observation that AG27-61 cells die rapidly When treated 
With 10 pM PHS at a loW cell density in de?ned medium. 
FolloWing PHS treatment, transformants Were spread at 
various densities on petri dishes containing de?ned medium 
lacking leucine, agarose in place of agar, and 10 or 20 pM 
PHS. Agarose Was used in place of agar to enhance the 
effective concentration of PHS Which appears to bind to 
components in regular bacterial agar. PHS-resistant colonies 
Were obtained from cells transformed With the genomic 
library but not from an equal number of cells transformed 
With the vector. 
Plasmid DNA from four PHS-resistant colonies Was res 
cued in Escherichia coli. The four plasmids, termed pIPC1, 
gave the same EcoRI restriction fragment pattern, indicating 
that they carry the same genomic DNA region. Each of the 
four pIPC1 DNA samples gave transformants When retrans 
formed into AGD27-61 and selected on de?ned medium 
lacking leucine and containing 1 or 12 pM PHS Whereas 
AGD27-61 transformed With the vector pRS315 gave no 
PHS-resistant transformants at the higher PHS concentra 
tion. These data shoW that the PHS-resistance phenotype is 
carried on pIPC1. 
The sphingolipid synthesis defect in AG27-61 cells, hap 
loid or diploid, prevents them from groWing on PYED plates 
having a pH of 4.1 (PYED-4. 1) When PHS is present 
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Whereas the parental strain 7R6 is able to groW because it 
makes sphingolipids. If pIPC1 restores sphingolipid synthe 
sis then AGD27-61 cells transformed With the plasmid 
should behave like 7R6 cells and groW on PYED-4.1 plates 
containing 25 pM PHS. (According to Patton et al., 174 J. 
Bacteriol. 7180 (1992). This expectation Was ful?lled by all 
30 AGD27-61 transformants tested While cells transformed 
With the vector did not groW. These data indicate that pIPC1 
carries a gene that complements the IPC synthase defect in 
AGD27-61 cells and restores sphingolipid synthesis When 
cells are fed PHS. 
To identify the genomic region carried in pIPC1, the 
nucleotide sequence at the ends of the genomic insert Was 
determined and used to search the Saccharomyces genome 
database (http://genome.WWW.stanford.edu). This search 
identi?ed a region of 4307 bases located on Chromosome XI 
betWeen coordinates 432,813 and 437,119. There is only one 
complete open-reading frame (YKL004W, AUR1) in this 
interval, Which is shoWn in SEQ ID No:1. 
As shoWn in the folloWing examples, AUR1 encodes IPC 
synthase. The gene has been renamed IPC1. 
C. The IPC1 gene restores IPC synthase activity to AG27-61 
cells. 
Membranes Were prepared from the control parental strain 
7R6 and from AG27-61 cells transformed With pIC1 or With 
a control vector (pRS315) and assayed for IPC synthase 
activity. Membranes from AG27-61 cells transformed With 
pIPC1 contained more IPC synthase activity than did the 
membranes from the 7R6 positive control cells (Table 1). 
Membranes from AG27-61 cells transformed With pRS315 
contained barely detectable enZyme activity (Table 1). 
TABLE 1 
Strains IPC Synthase activity (pMoles/min/mg protein) 
7R6 103 r 19 
AG27-61/pIPC1 159 r 9 
AG27-61/pRS315 0.2 r 0.07 
Restoration of IPC synthase activity by pIPC1 Was also 
examined by using an in vivo labeling procedure in Which 
cells Were incubated With a membrane-permeable ceramide, 
[3H]N-acetylsphinganine, to radiolabel sphingolipids, spe 
ci?cally IPC. The concentration of radiolabeled IPC 
increased in an almost linear fashion over the 3 hour course 
of the experiment in A27-61 cells transformed With pIPC1 
and, thus, these cells behave like the positive control cells, 
7R6 transformed With pRS315, Whereas AG27-61 cells 
transformed With pRS315 shoWed no synthesis of radiola 
beled product (FIG. 2). The data presented in Table 1 and 
FIG. 2 demonstrate that pIPC1 carries a gene that restores 
IPC synthase activity to AG27-61 cells. 
Example 2 
Initial Results from IPC Synthase Assay from C. 
albicans 
Using protocol similar to the procedure described by K0 
et al., 176 J. Bacteriol. 5181 (1994)., except that membranes 
from C. albicans at a concentration of 25 micrograms per 
reaction, and exogenous C6 ceramide, at a concentration of 
0.2 millimolar, With tritiated phosphatidylinositol 
(Amersham) in a reaction volume at 100 microliters at 30 
degrees centigrade at 2 hours the folloWing results Were 
obtained: Reaction conditions indicated incorporation of 
tritiated phosphoinositol into the C6 ceramide and Was 
inhibited by addition of R106-1 (also knoWn as Aureobasi 
6,022,684 
din A) at 20 micrograms per ml. (R106-1 is disclosed by 
Takesako et al. 44(9) J. Antibiot. 919 (1991) and Ikai et al., 
44 (9) J. Antibiot. 925 (1991). 
Example 3 
IPC Synthase Assay: FLUOR Method 
Strains YPH1Wt and SH2-3B AUR1R Were inoculated 
into YEPD (5 ml) supplemented With 20 pig/ml inositol and 
groWn overnight at 30° C. With shaking. Precultures Were 
then inoculated into 250 ml of YEPD+20 pig/ml myo-inositol 
and groWn overnight at 30° C. With shaking. Cells Were 
harvested at betWeen 5><107 cells/ml by centrifugation at 
2000><g for 10 minutes. Cells Were resuspended in ice-old 50 
mM potassium phosphate buffer, pH 7.0 and transferred to 
a 50 ml conical tube. The cells Were then Washed tWice With 
ice-cold 50 mM photassium phosphate buffer, pH 7.0. 
The cells Were then resuspended as a slurry in 5—10 ml of 
cold 50 mM potassium phosphate, pH 7.0, containing 5 mM 
DTT, 1 pig/ml aprotinin, 0.6 pMleupeptin, 1 mM PMSF and 
1 pig/ml peptatin A. The buffer With protease inhibitors Was 
made fresh just before use and kept cold. 
Next, the slurry Was tranferred to 2 ml tubes (Mini-beater 
tubes) and the cells Were pelleted by centrifugation at 
2000><g for ?ve minutes at 4° C. This Was repeated until the 
packed cell volume Was 50% of the tube volume or greater, 
but less than 75%. The remaining supernatant Was removed 
and 500 pmglass beads Were added to the top of the tube. To 
this Was added 50 mM potassium phosphate, DTT and 
protease inhibitors to ?ll up the remaining volume. The vial 
Was sealed With a screW cap. 
The cells Were then disrupted in a Mini-bead beater for 30 
seconds, ?ve times With 2—5 intervals on ice for cooling. The 
disrupted cell paste Was separated from the glass beads by 
?ltering through glass Wool into a chilled centrifuge tube on 
ice. The beads are rinsed With cold buffer Which Was pooled 
With the original ?ltrate. The centrifuge tube Was then 
centrifuged at 2000><g for ten minutes at 4° C. to remove cell 
debris. 
The supernatant Was transferred to an ultracentrifuge tube 
and the membranes Were pelleted by centrifugation at 100, 
000><g for sixty minutes at 4° C. The supernatant Was 
discarded and the pellet resuspended in cold buffer, DTT and 
protease inhibitors and reharvested by ultracentrifugation a 
second time. The ?nal membrane pellet Was resuspended in 
a minimal volume of cold buffer, DTT and protease inhibi 
tors and then transferred to a chilled dounce homogeniZer. 
The membranes Were homogeniZed With 5—6 strokes of a 
pestle on ice. The membranes Were then diluted With 1/3 
volume of glycerol (?nal 33%) glycerol) and mixed Well by 
inversion. Aliquots Were then placed in screW cap microfuge 
tuges and froZen on dry ice/ethanol and stored at —80° C. 
2>< master mix Was prepared using the folloWing recipe 
and With the folloWing consituents, to give as ?nal concen 
trations in the reaction: 
NBD—C6—ceramide (Molecular Probes) 5 ,uM 
phosphatidylinositol (Sigma — soybean) 1 mM 
CHAPS 2 mM 
potassium phosphate buffer, pH 7.0 50 mM 
Organic Co-solvent up to 2.5% 
(non-speci?c) protein concentration 0.45 mg/ml 
Final Volume 100 #1 
To the above solution, 46 pl NBD-C?-ceramide (0.1 
mg/ml in MeOH) and 142 pl phosphatidylinositol (10 mg/ml 
in CHCl3) Were added, and the product dried in vacuo. 
The dried product Was then redissolved by adding the 
folloWing ingredients in the folloWing order: 160 pl 20 mM 
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CHAPS, 560 pl deioniZed Water, 80 pl 0.5 M KPi buffer, pH 
7.0 and sonicated for 5 minutes. This Was considered “2x 
master mix”. 
Membrane stock Was thaWed and diluted to 1.8 mg/ml in 
0.05 M KPi buffer, pH 7.0 and kept on ice. 
Reaction Conditions 
50 pl of 2x master mix Was aliquoted into screW-cap 
microfuge tubes and kept at room temperature. 20 pl of 0.05 
M KPi buffer pH 7.0 Was added to each sample, folloWed by 
5 pl of test compound or extract in 50% (max) organic 
co-solvent. The reaction Was initiated by adding 25 pl of 
membrane stock to each reaction vessel, mixing, and incu 
bating at room temperature for 15 minutes. 
Reactions Were terminated by addition of 900 pl of ice 
cold absolute methanol. Samples Were then stored at —20° C. 
for at least one hour and then centrifuged at 14,000><g at 4° 
C. for 30 minutes. Fluorescence levels Were measured using 
the FLUOR method: RP-HPLC: 
FLUOR Method 
Column: Beckman Ultrasphere-ODS 
5 urn, 150 x 4 mm 
Buffer: 87% MeOH/13% 50 mM TEAP pH 5.85 
FloW: 1 ml/min 
Temp: Room temp 
Detector: Beckman Model 157 Fluorescence detector 
excitation: 475 nm 
emmission: 520 nm 
Analysis time: 12 min. 
Procedure 
100 pl of reaction supernatant Was placed in an HPLC 
microvial. 25 pl of reaction mixture Was injected and the 
chromatogram developed isocratically. Calculation Was per 
formed as % product formed: 
Under the stated conditions, depending on the speci?c 
activity of the membrane preparation, 10—15% product Was 
formed. The reaction pro?le in this range of product forma 
tion is in the linear portion of the reaction curve. 
Example 4 
Biotinylated Ceramide Reaction 
2>< master mix Was prepared using the folloWing recipe 
and With the folloWing consituents: 
Biotin—C6—ceramide 2 ,uM 
phosphatidylinositol (Sigma — soybean) 0.05 mM 
CHAPS 2 mM 
potassium phosphate buffer, pH 7.0 50 mM 
Organic Co-solvent up to 2.5% 
(non-speci?c) protein concentration 0.45 mg/ml 
Final Volume 50 #1 
To the above solution, 8.4 pl Biotin-C?-ceramide (0.1 
mg/ml in MeOH) and 35 pl phosphatidylinositol (1 mg/ml in 
CHCl3) and tritiated phosphatyldylinositol (10 Ci/mmol) 
Were added, and the product dried in vacuo. 
The dried product Was then redissolved by adding the 
folloWing ingredients in the folloWing order: 80 pl 20 mM 
CHAPS, 280 pl deioniZed Water, 40 pl 0.5 M KPi buffer, pH 
7.0 and sonicated for 5 minutes. This Was considered “2x 
master mix”. 
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Membrane stock Was thawed and diluted to 1.8 mg/ml in 
0.05 M KPi buffer, pH 7.0 and kept on ice. 
Reaction Conditions 
25 pl of 2x master mix Was aliquoted into screW-cap 
microfuge tubes and kept at room temperature. 10 pl of 0.05 
M KPi buffer pH 7.0 Was added to each sample, followed by 
2.5 pl of test compound or extract in 50% (max) organic 
co-solvent. The reaction Was initiated by adding 12.5 pl of 
12 
membrane stock to each reaction vessel, mixing, and incu 
bating at room temperature for 2 hours. 
Reactions Were terminated by addition of a suspension of 
streptavidin-conjugated scintillation proximity beads (4 mg 
in 200 pl) and the mixture incubated With the beads With 
shaking for one hour at room temperature. 
The radioactivity of the product Was counted in a scin 
tillation counter or in a microplate scintillation counter such 
as a Top-Count (Packard). 
SEQUENCE LISTING 
(1) GENERAL INFORMATION: 
(iii) NUMBER OF SEQUENCES: 1 
(2) INFORMATION FOR SEQ ID NO:1 : 
(i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 4307 base pairs 
(B) TYPE: nucleic acid 
(c) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
(ii) MOLECULE TYPE: DNA (genomic) 
(iii) HYPOTHETICAL: NO 
(iv) ANTI-SENSE: NO 
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1 : 
GATCTTTCAT CATTGTGACT GCCTAAAATA TCTTTCAAAA TTTCAGGAAT TTCACCGCCC 60 
TTCGATGGAA CGATATAAAA ATCCTTCTCG TATCTAGTTT TTGGCTTTAT ACCTGCAATG 120 
CGACCTTTGT TTTCCAGGGA GTCTACAACG TCGGCAAAAG TTGTCTTACT TTCACTATCA 180 
TTCGAAGGAA ATAATTGGTA TACTAATATA GCTCTAGAGC AAGAAATTTC CTTAAGATAT 240 
GGTGCAGCAG TGGTTGTAGG TAAGCGCCCT TCTACATACA GTTTTCCGTC ACCAATGGCT 300 
TCCTTGAAAA TATCCCGTCT TAACTTTTGT GAAGCCCCAA TGTAGTTTAG GTAACCTGTA 360 
AACTCAAGTC CTAAGCCGGG ATACAAAAAT GCGCAGTTTA AAGATTCTTC GTTGATTATT 420 
GTACTTGGGC TGGGTTCTTT CGAAATGGCA TGAGTCTGTT CTATTTTACT CTTATCGCTG 480 
TCGATACTGT CAATGTTGTG TAATCTTATG CTGTCTTTTG AGTACAAAAT ATCCTCTTGA 540 
GGTTCAGCGA TATCTTCGAT CAGCTCATCA CCCTTGTGGG TCTTAACGTA CATGGGTTTG 600 
TCAGGTACCT CCACGATAAA ATTTTCTAAG ATAATCTTAT CCCTTTTCTC TTTAAATTCT 660 
TGTAAGTCAG GATTTGCGAG TTCAGATGCG TTCATGTTCA CCAGTTTATT TAAAGGCAAT 720 
TTGCCCTCGA CAACGTGTGC CTTCAGTTCC AAATTTTTTT TATCCTTTAA ATTAGAGTAT 780 
AACGACCTCA CTTTCTCTGT GTATATCTTG TCCAAAGTAC CAAACTCGAC GTTAAGGCAA 840 
GCTTTGTAAA GTTCTTCTTC CAGATTGTGC GCAAACTCTT GCGATATCGA TATAACGTCT 900 
TTCCCATCAG GAAGCTCATA AAGTTTTGCC TCAATTGTTT CGGGAACGAT GAATTTGCTA 960 
AATAAGGTAG AGAACATTTT TTCTGCATTA TACCTCAGTT TGTGTTCTTT TTCGCTTTCA 1020 
AAATCTTTCC TAGTAGGCAT TTCGTTTTCG GCAGTATCAG ACTTGGCGGC ATCAATGCTT 1080 
TTATTCCTTT TTTTTGACCC ATTGGATTTC TTCACCTGTT TGGATTTGAT ATGAATTCCT 1140 
TTGGCACTAT CGGGGCTCCT TTTTCGTTTC CTAGGGCTTT CCTCATCAAG AAAGACATCT 1200 
GCATCATTGT CATCATGGTC ATTTACGGGC TTGTAAACAT CATCATGGTA ATCTTCATCC 1260 
TCTGAAACCT CTGCCTCCTT TGACGTTTCC AAATGTGCAT ACAATGATGG GTCGCACAAT 1320 
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TCACAGTAGT ACTTAGAATC TTCACTCATT AGCCCATCTA TGGTGTCTTT ACCATCAGTC 1380 
ATACATTTAA TATGCTGCCA AGTGTCACAG CCATCGCACT GTACCATGTC GCCATGCGAA 1440 
TATTCTGCAG CATCGTAGTT TTCATTGTTC GCCCCACACA GACATCTAAC ATAGCCCTCA 1500 
TCCGCTTCGT CTACTTCGTC TGTTCTTACA TTTTCAGTAT CTTTCCTTGG CTCCTGAGAA 1560 
GAATCAGACT TCTTATTCTT CTCTATGGCT GAATCAACTT TCTTTTTAGT TCTTTTTTTC 1620 
TTTGGTGCTT CAGTCTCCTC CTGTAACAAA TACTCAATAT ATTTATTCTG ACCCTTATTA 1680 
GATCTTGAAG AAGTACGGAC AGACATAATA AATTTAAACT AAATAAAAGC TAAAAGTAAA 1740 
AGAGAACCTA GGATAATCGA TAGCTCCCTG TGTATAGAAC AAGTCAAAAT ACTAAGATCT 1800 
CGTCAACCTA TCCTCTTTCA TTGCAAGCCT TTTGGCCAAA CTGCAGTCTG GGCATCCCTT 1860 
TGCATGTCTT GTGAAATAGT ATCCATCTCT CCCCAGCTCC CAGAAATGAT ATGAAAAGTT 1920 
ATTCGTGAAG AGTGATCCTA AAACTGAAAA AAGGAAAAAA CAAAAATGAG CTAAAAAAAC 1980 
CACAACAAAA GAATATCAAC TTCATTGCTT GGCGGGTCAT CGCTTTTTTA TTTCTTTCTG 2040 
TCAAAGAATA ATAAAGTGCC CATCAGTGTT CATATTTGTT ACAAAGTGGT TTTCTGATTT 2100 
GGTACTACTG CAGAGGCGTA TTTTTTGCTT CAGTTACCAT AGCGTAAGAA CACTAGCGAC 2160 
TTTTGTTCGT GAACCAACAG AGTAGGATTT CTACTGCTAC ATCTCTTAGG TAGTTGGTTA 2220 
GTCCGATCGC TCACTTTTGG TTGTTGTTAA GTACTTCATA AGTTTATCCT TTTCCTTTTT 2280 
CACACTGAGC TACTTTGGGT ATAGCTTTTG GCCCAAGGAT CTTTGAATTT TCTCCAAAAG 2340 
TACTTTATTT TATATCCTAC AGGTTGCGGT TTTCATATTT TAAAAAGCTT TTAATCATTC 2400 
CTTTGCGTAT GGCAAACCCT TTTTCGAGAT GGTTTCTATC AGAGAGACCT CCAAACTGCC 2460 
ATGTAGCCGA TTTAGAAACA AGTTTAGATC CCCATCAAAC GTTGTTGAAG GTGCAAAAAT 2520 
ACAAACCCGC TTTAAGCGAC TGGGTGCATT ACATCTTCTT GGGATCCATC ATGCTGTTTG 2580 
TGTTCATTAC TAATCCCGCA CCTTGGATCT TCAAGATCCT TTTTTATTGT TTCTTGGGCA 2640 
CTTTATTCAT CATTCCAGCT ACGTCACAGT TTTTCTTCAA TGCCTTGCCC ATCCTAACAT 2700 
GGGTGGCGCT GTATTTCACT TCATCGTACT TTCCAGATGA CCGCAGGCCT CCTATTACTG 2760 
TCAAAGTGTT ACCAGCGGTG GAAACAATTT TATACGGCGA CAATTTAAGT GATATTCTTG 2820 
CAACATCGAC GAATTCCTTT TTGGACATTT TAGCATGGTT ACCGTACGGA CTATTTCATT 2880 
TTGGGGCCCC ATTTGTCGTT GCTGCCATCT TATTCGTATT TGGTCCACCA ACTGTTTTGC 2940 
AAGGTTATGC TTTTGCATTT GGTTATATGA ACCTGTTTGG TGTTATCATG CAAAATGTCT 3000 
TTCCAGCCGC TCCCCCATGG TATAAAATTC TCTATGGATT GCAATCAGCC AACTATGATA 3060 
TGCATGGCTC GCCTGGTGGA TTAGCTAGAA TTGATAAGCT ACTCGGTATT AATATGTATA 3120 
CTACAGCTTT TTCAAATTCC TCCGTCATTT TCGGTGCTTT TCCTTCACTG CATTCCGGGT 3180 
GTGCTACTAT GGAAGCCCTG TTTTTCTGTT ATTGTTTTCC AAAATTGAAG CCCTTGTTTA 3240 
TTGCTTATGT TTGCTGGTTA TGGTGGTCAA CTATGTATCT GACACACCAT TATTTTGTAG 3300 
ACCTTATGGC AGGTTCTGTG CTGTCATACG TTATTTTCCA GTACACAAAG TACACACATT 3360 
TACCAATTGT AGATACATCT CTTTTTTGCA GATGGTCATA CACTTCAATT GAGAAATACG 3420 
ATATATCAAA GAGTGATCCA TTGGCTGCAG ATTCAAACGA TATCGAAAGT GTCCCTTTGT 3480 
CCAACTTGGA ACTTGACTTT GATCTTAATA TGACTGATGA ACCCAGTGTA AGCCCTTCGT 3540 
TATTTGATGG ATCTACTTCT GTTTCTCGTT CGTCCGCCAC GTCTATAACG TCACTAGGTG 3600 
TAAAGAGGGC TTAATGAGTA TTTTATCTGC AATTACGGAT ACGGTTGGTC TTATGTAGAT 3660 
ACATATAAAT ATATATCTTT TTCTTTCTTT TTCTTAGTCA GGATTGTCGT TTAGCATAAT 3720 
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ATACATGTAG TTTATTTAAT CACATACCAC TGATTATCTT TAGAATTTTA TAAATTTTTG 3780 
AAATAAATGG GTGGCTTTTA ATGGTGTCTA TGTTAAGTGA GGCTTTTAGA ATGCTCTTCC 3840 
TGCTTTGTTT ATTATATGTG TATGAAAGAT ATGTATGTAT TTACATGTGT TTGTAGCGTC 3900 
CCCAGTCAAA ACCTGTGCGC TATACCTAAA TGGATTGATA ATCTTCATTC ACTAATTCTA 3960 
AAATAGACTT CTTCCCCAAA GAACGGTGTA ACGATGAGGC TCTATCCAGC TGCTTATCTA 4020 
AATCAACTTT AACGATGGAT GATCTTATGA CACGGGGATC TTTCTTTAAA GTTCTTAGAA 4080 
TTTCAGACTG TACCGCAGCT GATGAATCAA ACAGCATTAA AAAGTGATAT GCTCGAAAAT 4140 
GTTTTTCCTG GTCTTTCTTC ATTATTTTAG GAAGATACCT TATGCCCATG GGTACAATGT 4200 
CCCTCACCAC ACCTCTGTTT TGAATAATCA GTTTCCCGAT TGTGGAAGAC AATTCTTTTG 4260 
CTTCCAACTT TGGCGCATTG GAGTTGGTTA TGCGAACAAG TCCGATC 4307 
What is claimed is: 
1. A method to determine the ability of a test compound 
to inhibit inositolphosphorylceramide (IPC) synthase, com 
prising: 
recombinantly expressing the Saccharomyces IPC1 gene 
in a plurality of cells transformed to express said gene, 
said cells being in homogeneous culture and located in 
a container useful for addition of liquids; and 
introducing excess ceramide and phosphatidylinositol, 
said ceramide or phosphatidylinositol carrying label for 
identi?cation, and test compound to said container; and 
subjecting said container and contents to ordinary condi 
tions necessary for ceramide conversion to phosphoi 
nositol ceramide; and 
identifying those test compounds Which inhibit ceramide 
conversion to phosphoinositol ceramide. 
2. The method of claim 1, Wherein the IPC1 gene is 
over-expressed. 
3. The method of claim 1, Wherein the cells are chosen 
from the group consisting of: E. coli; S. cerevisiae and S. 
pombe. 
4. A method of claim 1, Wherein the labeled starting 
substrate is a C2—C12 ceramide. 
5. A method of claim 4, Wherein the C2—C12 ceramide is 
NBD-CG-ceramide. 
6. A method of claim 4, Wherein the C2—C12 ceramide is 
BODIPY-CS-ceramide. 
7. A method of claim 4, Wherein the C2—C12 ceramide is 
N-hexanoyl-sphingosine. 
8. A method of claim 4, Wherein the C2—C12 ceramide is 
labeled With ?uorescent material. 
9. A method of claim 4, Wherein the C2—C12 ceramide is 
labeled With a radioactive material. 
10. Amethod of claim 9, Wherein the radioactive material 
is chosen from the group consisting of: 3H and 14C. 
11. A method to determine the ability of a test compound 
to inhibit IPC synthase, comprising: 
recombinantly expressing the Saccharomyces IPC1 gene 
in a plurality of cells transformed to express said gene, 
said cells being in homogeneous culture and located in 
a container useful for addition of liquids; and 
introducing excess biotinylated ceramide, labeled phos 
phatidylinositol and test compound to said container; 
and 
subjecting said container and contents to ordinary condi 
tions necessary for ceramide conversion; and 
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conjugating said biotinylated ceramide to streptavidin 
derivatiZed solid substrate; and 
identifying those test compounds Which inhibit ceramide 
conversion to phosphoinositol ceramide. 
12. A method of claim 11, Wherein the solid substrate is 
a plurality of scintillation proximity assay (SPA) beads. 
13. A method of claim 11, Wherein the phosphatidylinosi 
tol is labeled With label selected from the group consisting 
of tritium and 32F. 
14. A method to determine the ability of a test compound 
to inhibit IPC synthase, comprising: 
recombinantly expressing the Saccharomyces IPC1 gene 
in a plurality of cells transformed to express said gene, 
said cells being in homogeneous culture and located in 
a container useful for addition of liquids; and 
introducing excess biotinylated ceramide, phosphatidyli 
nositol and test compound to said container; and 
subjecting said container and contents to ordinary condi 
tions necessary for ceramide conversion; and 
conjugating said biotinylated ceramide to labeled 
streptavidin-derivatiZed solid substrate capable of ?lter 
separation; and 
?ltering to isolate the labeled streptavidin-derivatiZed 
solid substrate; and 
identifying those test compounds Which inhibit ceramide 
conversion to phosphoinositol ceramide. 
15. A method of claim 11, Wherein the solid substrate is 
a plurality of SPA beads. 
16. Amethod of claim 14, Wherein the phosphatidylinosi 
tol is labeled With label selected from the group consisting 
of tritium and 32F. 
17. A method to determine the ability of a test compound 
to inhibit IPC synthase, comprising: 
introducing into a container that contains a plurality of 
untransformed cells that express IPC synthase, excess 
biotinylated ceramide, labeled phosphatidylinositol, 
and test compound; and 
subjecting said container and contents to ordinary condi 
tions necessary for ceramide conversion to phosphoi 
nositol ceramide; and 
identifying those test compounds Which inhibit ceramide 
conversion to phosphoinositol ceramide. 
* * * * * 
